Modulari-T
Modulari-T has developed a new receptor architecture to reprogram multiple immune cell types to treat cancer and other diseases.
Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Cohort Year: 2023/24
Stream: Advanced Therapies
Modulari-T has developed a new receptor architecture to reprogram multiple immune cell types to treat cancer and other diseases.